Aclarion, Inc. (ACON) shareholders
ACONNasdaqServices-Medical LaboratoriesFiscal year ends December 31Also trades as ACONW
$1.56−0.03 (-1.89%)
Close on Nov 13, 2026Market cap $4.50MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0M
Shares held, 13F filers
Institutional holders
15
7 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
11 buys · 0 sales
Net bought $176.65K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| SEG Opportunity Fund, LLC | 244,043 | 9.98% | 13G (passive) | Mar 25, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ACON | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Bridgeway Capital Management, LLC | 19,480 | – | $56.10K | New | 0.00% |
| Captrust Financial Advisors | 17,059 | – | $49.13K | +2,500 | 0.00% |
| Vanguard Fiduciary Trust Co | 16,028 | – | $46.16K | New | 0.00% |
| Susquehanna International Group, Llp | 15,355 | – | $44.22K | New | 0.00% |
| Geode Capital Management, LLC | 12,128 | – | $34.93K | −19,087 | 0.00% |
| XTX Topco Ltd | 11,038 | – | $31.79K | New | 0.00% |
| Bank Of Montreal /Can/ | 10,000 | – | $28.80K | – | 0.00% |
| Vanguard Capital Management LLC | 6,782 | – | $19.53K | – | 0.00% |
| Osaic Holdings, Inc. | 5,000 | – | $14.40K | −29,945 | 0.00% |
| UBS Group AG | 1,968 | – | $5.67K | −7,679 | 0.00% |
| Barclays PLC | 283 | – | $815 | New | 0.00% |
| Clear Street Group Inc. | 103 | – | $297 | +100 | 0.00% |
| Wells Fargo & Company/Mn | 100 | – | $288 | New | 0.00% |
| Caitong International Asset Management Co., Ltd | 4 | – | $12 | New | 0.00% |
| Danske Bank A/S | 1 | – | $3 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 15 | 0M | 7 / 2 | 3 / 2 | 0M | 0M |
| Q1 2026 | 10 | 0M | 4 / 2 | 0 / 2 | 0M | 0M |
| Q4 2025 | 8 | 0M | 2 / 1 | 1 / 2 | 0M | 0M |
| Q3 2025 | 8 | 0M | 5 / 1 | 0 / 1 | 0M | 0M |
| Q2 2025 | 5 | 0M | 0 / 3 | 0 / 1 | 0M | 0M |
| Q1 2025 | 6 | 0M | 6 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
4 funds held ACON in Q2 2026, 14% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ACON | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 21,944 | – | $71.98K | 0.00% | May 31, 2026 |
| Ultra-Small Company Fund | 19,480 | – | $56.10K | 0.06% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 6,782 | – | $19.53K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 477 | – | $1.56K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Brent Ness | Chief Executive Officer, Director | 111,534 | Aug 17, 2026 |
| Jeffrey John Thramann | Executive Chairman, Director | 100,000 | Jun 12, 2026 |
| Gregory A. Gould | CFO | 60,000 | Aug 18, 2026 |
| Amanda M. Williams | Director | 25,857 | Aug 19, 2026 |
| William Wesemann | Director | 23,713 | Aug 17, 2026 |
| David K. Neal | Director | 30,002 | Aug 17, 2026 |
| Ryan Bond | Director | 76,122 | Aug 17, 2026 |
| Stephen Deitsch | Director | 20,000 | Jun 12, 2026 |
| Scott Breidbart | Director | 25,664 | Jun 12, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Amanda M. Williams Director | Aug 17, 2026 | Buy | +5,857 | $2.73 | $15.99K | 25,857 |
| Gregory A. Gould CFO | Aug 14, 2026 | Buy | +10,000 | $2.45 | $24.50K | 60,000 |
| Brent Ness Chief Executive Officer, Director | Aug 13, 2026 | Buy | +5,234 | $2.31 | $12.09K | 111,534 |
| William Wesemann Director | Aug 13, 2026 | Buy | +2,150 | $2.34 | $5.03K | 23,713 |
| Ryan Bond Director | Aug 13, 2026 | Buy | +21,122 | $2.37 | $50.06K | 76,122 |
| David K. Neal Director | Aug 13, 2026 | Buy | +7,500 | $2.40 | $18.00K | 30,002 |
| Stephen Deitsch Director | Jun 11, 2026 | Award | +20,000 | – | – | 20,000 |
| David K. Neal Director | Jun 11, 2026 | Award | +20,000 | – | – | 22,502 |
| Ryan Bond Chief Strategy Officer | Jun 11, 2026 | Award | +55,000 | – | – | 55,000 |
| Jeffrey John Thramann Executive Chairman, Director | Jun 11, 2026 | Award | +100,000 | – | – | 100,000 |
| Gregory A. Gould Chief Financial Officer | Jun 11, 2026 | Award | +50,000 | – | – | 50,000 |
| William Wesemann Director | Jun 11, 2026 | Award | +20,000 | – | – | 21,563 |
| Brent Ness Chief Executive Officer, Director | Jun 11, 2026 | Award | +100,000 | – | – | 106,300 |
| Amanda M. Williams Director | Jun 11, 2026 | Award | +20,000 | – | – | 20,000 |
| Scott Breidbart Director | Jun 11, 2026 | Award | +20,000 | – | – | 25,664 |
| Scott Breidbart Director | May 12, 2026 | Buy | +5,664 | $3.18 | $18.01K | 5,664 |
| David K. Neal Director | May 11, 2026 | Buy | +2,500 | $3.10 | $7.75K | 2,502 |
| Brent Ness Chief Executive Officer, Director | May 11, 2026 | Buy | +6,289 | $3.18 | $20.00K | 6,300 |
| William Wesemann Director | May 6, 2026 | Buy | +1,562 | $3.30 | $5.15K | 1,563 |
| Brent Ness Chief Executive Officer, Director | Nov 26, 2025 | Buy | +10 | $6.20 | $62 | 11 |
| Jeffrey John Thramann Executive Chairman | Mar 28, 2023 | Other | −1 | $1000.00 | $1.00K | 0 |
| Jeffrey John Thramann Executive Chairman, Director | Feb 16, 2023 | Buy | +1 | $1000.00 | $1.00K | 1 |
| John Paul Lorbiecki Chief Financial Officer | Dec 29, 2022 | Buy | +4,100 | $0.43 | $1.76K | 4,100 |
| John Paul Lorbiecki Chief Financial Officer | Dec 29, 2022 | Buy | +18,304.44 | $0.45 | $8.24K | 22,404 |
| Brent Ness Chief Executive Officer, Director | Dec 29, 2022 | Buy | +8,500 | $0.51 | $4.34K | 11,789 |
| Brent Ness Chief Executive Officer, Director | Dec 29, 2022 | Buy | +7,711 | $0.58 | $4.47K | 19,500 |
| Brent Ness Chief Executive Officer, Director | Dec 28, 2022 | Buy | +2,289 | $0.42 | $961 | 3,289 |
| David K. Neal Director | Dec 2, 2022 | Other | +152,128 | – | – | 186,528 |
| David K. Neal Director | Dec 2, 2022 | Other | −152,128 | – | – | 186,528 |
| Michael W. Dirks – | Dec 2, 2022 | Other | −1,091,894 | – | – | 0 |
| Ryan Bond Chief Strategy Officer | Apr 22, 2022 | Buy | +20,000 | $2.80 | $56.00K | 20,000 |
| Brent Ness Chief Executive Officer, Director | Apr 21, 2022 | Buy | +1,000 | $4.35 | $4.35K | 1,000 |
| David K. Neal Director | Apr 21, 2022 | Buy | +34,400 | $4.35 | $149.64K | 34,400 |
| William Wesemann Director | Apr 21, 2022 | Buy | +11,000 | $4.35 | $47.85K | 52,736 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
1.6
At 0M shares a day
Change since last report
-12.8%
From 0M shares
Short volume, 20 days
38.5%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Aclarion's stock actually held short. Settlement fails (shares not delivered on time) peaked at 4,403 shares on Sep 8, 2026 over the last 90 days.
See a number that looks wrong?